• Technical Aspects of Clinical Proteomics
• 50 min
  1. Proteomic technologies and targets: an overview

  • Dr. Walter Kolch
• 35 min
  2. A concept for multi-marker approaches in clinical proteomics

  • Dr. Bernd Mayer
• Disease-Specific Aspects of Clinical Proteomics
• 53 min
  3. Urinary proteomics in kidney and cardiovascular disease

  • Prof. Harald Mischak
• 40 min
  4. Proteomics in diabetic kidney disease

  • Prof. Peter Rossing
• 34 min
  5. Proteomics in cardiovascular disease: clinical considerations

  • Dr. Christian Delles
• 22 min
  6. Clinical proteomics in the investigation of bladder cancer

  • Prof. Antonia Vlahou
• 33 min
  7. Application of proteomics in fetal and neonatal medicine

  • Dr. Joost P. Schanstra
• 51 min
  8. Clinical proteomics in neurodegenerative disease

  • Dr. Holger Jahn
• 37 min
  9. Clinical proteomics in gastrointestinal cancers

  • Dr. Jochen Metzger
• Archived Lectures *These may not cover the latest advances in the field
• 38 min
  10. Proteomics in kidney disease: clinical considerations

  • Prof. Peter Rossing

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Initial roadmap of clinical proteomics
4. Samples
5. Biomarkers in bio-fluids
6. Urine is a pool of biomarkers
7. One-dimensional view of urinary protein content
8. Reduce complexity
9. Proteome analysis
10. Capillary electrophoresis and mass spectrometry
11. The low molecular weight urinary proteome
12. Statistics
13. The clinical question in obstructive nephropathy
14. The problem of UPJ obstruction
15. Definitions
16. Training (roadmap)
17. Training (experiment)
18. Panels of peptides differentiate between groups
19. Validation in a blinded population
20. Small scale prospective blinded validation
21. CE-MS prediction versus clinical evolution
22. Large scale validation (roadmap)
23. Large scale validation (experiment)
24. “Small” single center validation
25. UPJ obstruction follow-up studied with proteomics
26. UPJ obstruction & permanent lesions (animal)
27. UPJ obstruction & permanent lesions (newborn)
28. Experimental setup
29. Difference controls versus UPJ
30. Increased secretion
31. Observations
32. UPJ scores using CKD pattern
33. Results explanation
34. Biomarkers in fetal urine
35. Prediction of post-natal renal function in PUV
36. Postnatal renal function and prenatal counseling
37. Training (PUV)
38. Validation
39. Prediction using the 12PUV model in FU
40. Comparison with “gold standards”
41. Conclusions
42. Credits

Topics Covered

• Application of proteomics in fetal and neonatal medicine
• Principles
• Samples
• Techniques
• Statistics
• Application to obstructive nephropathy in newborns
• Application in neonatal medicine
• Conclusion

Links

Series:

• Clinical Proteomics

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Methods

Therapeutic Areas:

• Gynaecology & Obstetrics

Talk Citation

Publication History

• Published on November 5, 2013

Financial Disclosures

• Dr. Joost P. Schanstra has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.